Mandate

Vinge Advises Smedvig Capital

May 14, 2008

Vinge advised London based Norwegian private equity company Smedvig Capital in connection to their investment in SelStor AB. SelStor AB, founded in 2006, will provide self-storage warehouses to private individuals and companies. Smedvig’s invests SEK 100 million (through Peder Smedvig Capital Fund IX LP) via a variety of bonds and receives, after full subscription, 45 percent of the shares. In addition Smedvig shall provide shareholder’s loans to a value of SEK 75 million. Vinge advised Smedvig on the establishment and negotiation of the subscription agreement, shareholder’s agreement and loan, employment agreements and the customary due diligence process.

Vinge’s team included partner Ulf Sällnäs joined by Hillevi Myhre, Sarah Khalil, Johan Bocander, Maria Schultzberg, Maria Doeser, Åsa Gotthardsson, Anders Frick, Johan Cederblad and Pernilla Warg.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026